The predictors of successful methotrexate treatment of tubal ectopic pregnancy
Authors:
Open Access
- 12 June 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 44 (1) , 2361456
Abstract
The pre-treatment characteristics of the patient and ectopic pregnancy to determine the patients who are likely to successfully respond to methotrexate (MTX) therapy remain controversial. This study investigated the outcomes of ectopic pregnancy after one and two MTX doses and their independent predictors. Retrospective cross-sectional study of women who consented to MTX treatment in 2017-2018 at our institution (N = 317). Of these, patients with Caesarean scar pregnancies were excluded because they require different treatment protocols (n = 25). All patients were treated according to our institution's protocol based on international guidelines and standardised across the three hospitals included in the current study. We retrieved patients' demographics, laboratory, ultrasonography, and clinical characteristics from our hospital database. Serum β-human chorionic gonadotropin (β-hCG) was measured using electrochemiluminescence immunoassay; ectopic pregnancy was diagnosed using ultrasonography (transvaginal probe). Two ninety-two patients were included in the current analysis. Age, pre-treatment β-hCG levels, sonographic presence of yolk sac, presence of foetal cardiac activity, and pelvic pain were significantly different between patients with successful and unsuccessful outcomes. Younger age (adjusted odds ratio [aOR] 2.33, 95% confidence interval (CI) 1.16-4.66, p = .017), no pelvic pain (aOR 2.65, 95%CI 1.03-6.83, p = .043), lower initial β-hCG level (aOR 1.32, 95%CI 1.08-1.59, p = .005), and absence of foetal cardiac activity (aOR 12.63; 95% CI 1.04-153.6; p = .047) were independently associated with success. Treatment failure odds were >2 folds higher for each 10-year age increase (p = .017), 32% higher for each 1000 IU/L increase in initial β-hCG level (p = .005), and >2 folds higher in presence of pelvic pain (p = .043). MTX is effective in most patients, averting invasive surgery, which might affect fertility. Pre-treatment β-hCG levels, age, pelvic pain, and foetal cardiac activity was independently associated with outcomes. Research should assess the relationship between the ectopic pregnancy size and treatment outcomes and refine β-hCG titres where treatment would be ineffective.Keywords
This publication has 42 references indexed in Scilit:
- How to measure size of tubal ectopic pregnancy on ultrasoundUltrasound in Obstetrics & Gynecology, 2018
- Disparities in the management of ectopic pregnancyAmerican Journal of Obstetrics and Gynecology, 2017
- Predictors of Success of a Single-Dose Methotrexate in the Treatment of Ectopic PregnancyThe Journal of Obstetrics and Gynecology of India, 2015
- Correlation of the volume of ectopic pregnancy and MTX therapy outcome: a retrospective cohort studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2015
- Cut-off value of initial serum β-hCG level predicting a successful MTX therapy in tubal ectopic pregnancy: a retrospective cohort studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2014
- Methotrexate for ectopic pregnancy: when and howArchives of Gynecology and Obstetrics, 2014
- Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008Archives of Gynecology and Obstetrics, 2013
- Yolk sac on transvaginal ultrasound as a prognostic indicator in the treatment of ectopic pregnancy with single-dose methotrexateAmerican Journal of Obstetrics and Gynecology, 2009
- Use of “2-dose” regimen of methotrexate to treat ectopic pregnancyFertility and Sterility, 2007
- The non‐surgical management of ectopic pregnancyUltrasound in Obstetrics & Gynecology, 2005